
Myeloproliferative Neoplasms
Latest News
Video Series
Latest Videos
Shorts

Podcasts
CME Content
More News

In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.

Data showing the bioequivalence of extended-release ruxolitinib tablets vs reference ruxolitinib supported the FDA approval across multiple indications.

Findings from a phase 1 trial showed no adverse effects higher than grade 3 among those who received ruxolitinib/abemaciclib for advanced myelofibrosis.

Involving transplant physicians early on is critical in myelofibrosis therapy, said Nicolaus Kröger, MD.

Data from the phase 3 SENTRY trial showed a promising survival signal with selinexor plus ruxolitinib among patients with myelofibrosis.

Rusfertide could become a part of every patient’s treatment history for polycythemia vera, according to Andrew Kuykendall, MD.

Metformin, a type 2 diabetes drug, was found to reduce myeloproliferative neoplasm development.

Results from the phase 3 MOMENTUM trial led momelotinib to being approved by the European Commission for patients with myelofibrosis plus anemia and splenomegaly.

Dose reductions and interruptions of navitoclax plus ruxolitinib in the TRANSFORM-1 trial appear to be mostly due to thrombocytopenia, according to Naveen Pemmaraju, MD.

An AI algorithm was created to distinguish prefibrotic primary myelofibrosis and essential thrombocythemia from each other.

If momelotinib receives approval in the European Union, it will become the only agent for the treatment of myelofibrosis coupled with moderate to severe anemia.

John O. Mascarenhas, MD, led a panel discussion on myelofibrosis management including the use of JAK inhibitors and transplantation.

Patients with myelofibrosis and anemia can now receive treatment with momelotinib following the agent’s approval by the FDA based on results from the phase 3 MOMENTUM trial.

Mohammad Bakri Hammami, MD, highlights a need to address socio-racial disparities among Black and non-Black patients with primary myelofibrosis to ensure that everyone receives high-quality treatment.

Selinexor plus ruxolitinib is under investigation as a treatment for JAK inhibitor-naïve patients with myelofibrosis as part of the phase 3 XPORT-MF-034 trial.

Data from the phase 2 MANIFEST study suggest that pelabresib plus ruxolitinib may improve the standard of care for patients with myelofibrosis who are naïve to treatment with JAK inhibitors.

Most treatment-related adverse effects were low-grade following treatment with BMS-986158 plus ruxolitinib or fedratinib in a population of patients with intermediate- or high-risk myelofibrosis.

The phase 3 LIMBER-304 trial examining parsaclisib with ruxolitinib vs matched placebo will be discontinued after an interim analysis concluded it would likely miss the primary end point.

An expert from the University of Texas MD Anderson Cancer Center says momelotinib may lead to decreased transfusion dependence vs danazol in myelofibrosis and intermediate- or high-risk anemia.

Tamibarotene is a first-in-class oral first-in-class selective retinoic acid receptor α agonist that is being evaluated in combination with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome.
















































